X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (321) 321
humans (318) 318
hematology (273) 273
european leukemianet (254) 254
oncology (193) 193
female (185) 185
male (185) 185
middle aged (172) 172
adult (158) 158
aged (155) 155
prognosis (128) 128
treatment outcome (117) 117
chronic myeloid leukemia (109) 109
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (109) 109
chronic myelogenous leukemia (96) 96
young adult (94) 94
european-leukemianet (91) 91
leukemia (91) 91
recommendations (88) 88
aged, 80 and over (87) 87
adolescent (86) 86
imatinib (86) 86
antineoplastic agents - therapeutic use (76) 76
imatinib mesylate (74) 74
protein kinase inhibitors - therapeutic use (73) 73
tyrosine kinase inhibitors (72) 72
follow-up (71) 71
cancer (67) 67
hemic and lymphatic diseases (67) 67
leukemia, myeloid, acute - genetics (67) 67
leukemia, myelogenous, chronic, bcr-abl positive - genetics (64) 64
mutation (64) 64
fusion proteins, bcr-abl - genetics (57) 57
cml (56) 56
analysis (55) 55
hematology, oncology and palliative medicine (54) 54
leukemia, myeloid, acute - mortality (53) 53
pyrimidines - therapeutic use (53) 53
transplantation (53) 53
diagnosis (51) 51
dasatinib (50) 50
acute myeloid leukemia (49) 49
disease-free survival (49) 49
chronic myeloid-leukemia (47) 47
chronic-phase (45) 45
leukemia, myeloid, acute - therapy (45) 45
retrospective studies (45) 45
therapy (45) 45
care and treatment (44) 44
research (44) 44
acute myeloid-leukemia (43) 43
piperazines - therapeutic use (43) 43
bcr-abl (42) 42
follow-up studies (42) 42
management (42) 42
myelodysplastic syndromes (42) 42
survival (42) 42
nilotinib (39) 39
survival analysis (39) 39
minimal residual disease (38) 38
interferon-alpha (37) 37
leukemia, myelogenous, chronic, bcr-abl positive - mortality (37) 37
acute myelogenous leukemia (36) 36
survival rate (35) 35
cytogenetics (34) 34
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (34) 34
leukemia, myeloid, acute - diagnosis (34) 34
tyrosine (34) 34
aml (33) 33
flow cytometry (33) 33
myelodysplastic syndromes - diagnosis (33) 33
remission induction (33) 33
stem-cell transplantation (33) 33
gene expression (32) 32
medicine & public health (32) 32
benzamides (31) 31
leukemia, myeloid, chronic-phase - drug therapy (31) 31
bone marrow (30) 30
patients (30) 30
transplantation, homologous (30) 30
adults (28) 28
antineoplastic agents (28) 28
hematopoietic stem cell transplantation (28) 28
molecular response (28) 28
pyrimidines - administration & dosage (28) 28
risk factors (28) 28
stem cells (27) 27
suboptimal response (27) 27
time factors (27) 27
abridged index medicus (26) 26
classification (26) 26
health aspects (26) 26
antimitotic agents (25) 25
kaplan-meier estimate (25) 25
leukemia, myeloid, acute - drug therapy (25) 25
tyrosine kinase inhibitor (25) 25
chemotherapy (24) 24
patients receiving imatinib (24) 24
pyrimidines - adverse effects (24) 24
antineoplastic agents - administration & dosage (23) 23
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Haematologica, ISSN 0390-6078, 01/2011, Volume 96, Issue 1, pp. 156 - 162
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 10/2013, Volume 14, Issue 15, pp. 2005 - 2010
Journal Article
European Journal of Haematology, ISSN 0902-4441, 12/2015, Volume 95, Issue 6, pp. 558 - 565
Background We conducted a phase II study to evaluate the efficacy and safety of dasatinib in Japanese patients with imatinib‐resistant or imatinib‐intolerant... 
molecular response ≧4.5 log reduction | chronic myeloid leukemia | dasatinib | major molecular response | European LeukemiaNet 2013 recommendations | Dasatinib | Molecular response ≧4.5 log reduction | Major molecular response | Chronic myeloid leukemia | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | ACCELERATED PHASE | 1ST-LINE IMATINIB | TYROSINE KINASE | FOLLOW-UP | KINASE INHIBITOR | HIGH-DOSE IMATINIB | RANDOMIZED PHASE-2 | HEMATOLOGY | molecular response >= 4.5 log reduction | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Young Adult | Imatinib Mesylate - therapeutic use | Antineoplastic Agents - adverse effects | Imatinib Mesylate - adverse effects | Imatinib Mesylate - administration & dosage | Adult | Female | Leukemia, Myeloid, Chronic-Phase - drug therapy | Kaplan-Meier Estimate | Treatment Outcome | Leukemia, Myeloid, Chronic-Phase - diagnosis | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Adolescent | Aged | Mutation | Leukemia, Myeloid, Chronic-Phase - genetics | Antimitotic agents | Sects | Antineoplastic agents
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 8, pp. 1405 - 1412
Journal Article
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 07/2019, Volume 19, Issue 7, pp. e377 - e384
In the European LeukemiaNet (ELN) 2013 recommendations, chronic myeloid leukemia (CML) patients with warning response (WR) were suggested to be monitored... 
European LeukemiaNet (ELN) | Imatinib | Warning | Chronic myeloid leukemia | Tyrosine kinase inhibitor | MANAGEMENT | ONCOLOGY | HEMATOLOGY
Journal Article
Leukemia, ISSN 0887-6924, 07/2011, Volume 25, Issue 7, pp. 1168 - 1173
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 06/2013, Volume 31, Issue 18, pp. 2361 - 2362
Journal Article
Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 10/2006, Volume 131, Issue 43, pp. 2423 - 2426
Journal Article
Leukemia Research, ISSN 0145-2126, 08/2018, Volume 71, pp. 75 - 81
Diagnosis of myelodysplastic syndromes (MDS) is not straightforward when objective data, such as blast excess and abnormal cytogenetics, are lacking. Expert... 
Side scatter | Ogata score | Flow cytometry | CD34 | Myelodysplastic syndromes | CD33 | CELLS | LEUKEMIANET WORKING GROUP | STANDARDIZATION | EUROPEAN LEUKEMIANET | SYNDROMES MDS | VALIDATION | CLASSIFICATION | IMPACT | ONCOLOGY | SCORING SYSTEM | HEMATOLOGY | UTILITY | Analysis | Oncology, Experimental | Cytogenetics | Diagnosis | Research | Cancer
Journal Article
BLOOD, ISSN 0006-4971, 10/2016, Volume 128, Issue 17, pp. 2130 - 2134
Favorable-risk human acute myeloid leukemia (AML) engrafts poorly in currently used immunodeficient mice, possibly because of insufficient environmental... 
RESPONSES | CELLS | HEMATOLYMPHOID SYSTEM MICE | EUROPEAN LEUKEMIANET | ADULTS | ACUTE MYELOID-LEUKEMIA | HEMATOLOGY | EXPRESSION
Journal Article